The company still sees a potential path forward for tomivosertib in acute myeloid leukemia, where its mechanistic rationale is distinct from the one in NSCLC.
eFFECTOR Therapeutics, Inc. is placing its bets on a breast cancer drug candidate following the failure in a mid-stage trial of tomivosertib for non-small cell lung cancer (NSCLC), an indication where some had forecast blockbuster sales. However, the company is not yet giving up on tomivosertib, which is also in early-stage development for acute myeloid leukemia (AML).
The biotech company announced 4 April that the Phase II KICKSTART trial combining tomivosertib with Merck & Co., Inc.’s...
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
Multi-blockbuster falls short in a giant cell arteritis study.
